Pathological Complete Remission and Long-Term Outcome—What Do We Know in 2016?

The tale of HER2-positive breast cancer is a story of success. From the identification of HER2 protein overexpression as a strong predictor of poor outcome, to the introduction of the HER2-directed antibody trastuzumab in the metastatic setting, and to the neoadjuvant trastuzumab trials, major improvements in the outcome of patients with HER2-positive breast cancer have been achieved.

 The Lancet Oncology

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.